examination in the assessment of suspected autonomic dysfunction. For those clinicians or researchers who choose to pursue catechol testing in their patients or subjects, the authors provide a detailed protocol, in Table 2 , for collecting and processing samples.
Perhaps most helpful for the clinician is the extended discussion of many of the common and uncommon autonomic disorders and their respective neurochemical patterns (summarized in Table 1 ). For example, the clinician is often faced with a patient with parkinsonism and some degree of orthostatic lightheadedness. Is this run-of-the-mill Parkinson disease (PD), dementia with Lewy bodies (DLB), or multiple system atrophy (MSA)? This question can sometimes be answered with the help of neuroimaging [6] , cardiac metaiodobenzylguanidine scintigraphy [8] , or autonomic reflex screen and thermoregulatory sweat test [5] data, but these diagnostic tools are not always available or the results revealing. Enter plasma catechol testing. OH will be associated with a low 3,4-dihydroxyphenylglycol (DHPG) to NE ratio in PD, low NE and blunted orthostatic change in DLB, and normal NE when supine and standing and normal DHPG in MSA. The authors classify the catechol pattern in MSA as unhelpful, but in fact normal NE and DHPG in the setting of parkinsonism and OH is quite telling. Similarly, normal NE (and DHPG) predicts conversion to a central synucleinopathy in patients whose initial phenotype suggests pure autonomic failure [4, 7] .
Goldstein and Cheshire have brought together a great deal of work on clinical catechol neurochemistry in a concise review. While catechol testing is not necessary in every patient, it can be informative in many and diagnostic in a few. Such testing should be considered as we seek additional clarity in the often murky world of "dysautonomia".
